APOBEC Mutagenesis, Kataegis, Chromothripsis in EGFR-Mutant Osimertinib-Resistant Lung Adenocarcinomas

Signatures of mutational processes in human cancer

Ludmil B. Alexandrov, S. Nik-Zainal, D. Wedge, et al.. (2013). Nature. Cited 8,903 times. https://doi.org/10.1038/nature12477

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

Z. Gu, R. Eils, M. Schlesner. (2016). Bioinformatics. Cited 7,662 times. https://doi.org/10.1093/bioinformatics/btw313

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

J. Soria, Y. Ohe, J. Vansteenkiste, et al.. (2018). The New England Journal of Medicine. Cited 4,126 times. https://doi.org/10.1056/NEJMoa1713137

Maftools: efficient and comprehensive analysis of somatic variants in cancer

A. Mayakonda, D. Lin, Y. Assenov, et al.. (2018). Genome Research. Cited 3,656 times. https://doi.org/10.1101/gr.239244.118

Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients

A. Zehir, R. Benayed, Ronak H. Shah, et al.. (2017). Nature medicine. Cited 2,867 times. https://doi.org/10.1038/nm.4333

The repertoire of mutational signatures in human cancer

Ludmil B. Alexandrov, Jaegil Kim, N. Haradhvala, et al.. (2018). Nature. Cited 2,821 times. https://doi.org/10.1038/s41586-020-1943-3

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

M. Mirza, B. Monk, J. Herrstedt, et al.. (2016). The New England journal of medicine. Cited 2,046 times. https://doi.org/10.1056/NEJMOA1611310

Absolute quantification of somatic DNA alterations in human cancer

S. Carter, K. Cibulskis, E. Helman, et al.. (2012). Nature biotechnology. Cited 1,892 times. https://doi.org/10.1038/nbt.2203

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Donavan T. Cheng, Talia Mitchell, A. Zehir, et al.. (2015). The Journal of molecular diagnostics : JMD. Cited 1,871 times. https://doi.org/10.1016/j.jmoldx.2014.12.006

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

T. André, K. Shiu, Tae Won Kim, et al.. (2020). The New England journal of medicine. Cited 1,850 times. https://doi.org/10.1056/nejmoa2017699

Mutational Processes Molding the Genomes of 21 Breast Cancers

S. Nik-Zainal, Ludmil B. Alexandrov, D. Wedge, et al.. (2012). Cell. Cited 1,846 times. https://doi.org/10.1016/j.cell.2012.04.024

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

A. González-Martín, B. Pothuri, I. Vergote, et al.. (2019). Obstetrical & Gynecological Survey. Cited 1,631 times. https://doi.org/10.1097/OGX.0000000000000756

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

A. Leonetti, Sugandhi Sharma, R. Minari, et al.. (2019). British Journal of Cancer. Cited 1,062 times. https://doi.org/10.1038/s41416-019-0573-8

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

E. D. de Bruin, N. Mcgranahan, R. Mitter, et al.. (2014). Science. Cited 1,033 times. https://doi.org/10.1126/science.1253462

FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing

R. Shen, V. Seshan. (2016). Nucleic Acids Research. Cited 957 times. https://doi.org/10.1093/nar/gkw520

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

L. Marcus, S. Lemery, P. Keegan, et al.. (2019). Clinical Cancer Research. Cited 901 times. https://doi.org/10.1158/1078-0432.CCR-18-4070

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

Jianjun Zhang, J. Fujimoto, Jianhua Zhang, et al.. (2014). Science. Cited 900 times. https://doi.org/10.1126/science.1256930

The evolutionary history of 2,658 cancers

M. Gerstung, Clemency Jolly, I. Leshchiner, et al.. (2017). Nature. Cited 891 times. https://doi.org/10.1038/s41586-019-1907-7

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

E. V. Van Allen, N. Wagle, A. Sucker, et al.. (2014). Cancer discovery. Cited 841 times. https://doi.org/10.1158/2159-8290.CD-13-0617

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

N. Mcgranahan, F. Favero, E. D. de Bruin, et al.. (2015). Science Translational Medicine. Cited 620 times. https://doi.org/10.1126/scitranslmed.aaa1408

APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.

C. Swanton, N. Mcgranahan, G. Starrett, et al.. (2015). Cancer discovery. Cited 433 times. https://doi.org/10.1158/2159-8290.CD-15-0344

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

J. Lee, J. Lee, Sehui Kim, et al.. (2017). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 404 times. https://doi.org/10.1200/JCO.2016.71.9096

Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis

Mia Petljak, Ludmil B. Alexandrov, Jonathan S Brammeld, et al.. (2019). Cell. Cited 369 times. https://doi.org/10.1016/j.cell.2019.02.012

Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes.

M. Offin, J. Chan, M. Tenet, et al.. (2019). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Cited 344 times. https://doi.org/10.1016/j.jtho.2019.06.002

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

A. Schoenfeld, J. Chan, Daisuke Kubota, et al.. (2020). Clinical Cancer Research. Cited 287 times. https://doi.org/10.1158/1078-0432.CCR-19-3563

Detecting the mutational signature of homologous recombination deficiency in clinical samples

D. Gulhan, J. Lee, G. Melloni, et al.. (2019). Nature Genetics. Cited 263 times. https://doi.org/10.1038/s41588-019-0390-2

Biological Relevance of Colony Morphology and Phenotypic Switching by Burkholderia pseudomallei

N. Chantratita, V. Wuthiekanun, K. Boonbumrung, et al.. (2006). Journal of Bacteriology. Cited 170 times. https://doi.org/10.1128/JB.01258-06

Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

Subramanian Venkatesan, R. Rosenthal, N. Kanu, et al.. (2018). Annals of Oncology. Cited 142 times. https://doi.org/10.1093/annonc/mdy003

APOBEC Enzymes as Targets for Virus and Cancer Therapy.

M. E. Olson, R. Harris, Daniel A. Harki. (2017). Cell chemical biology. Cited 141 times. https://doi.org/10.1016/j.chembiol.2017.10.007

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

N. Roper, Anna L. Brown, Jun S. Wei, et al.. (2020). Cell Reports Medicine. Cited 140 times. https://doi.org/10.1016/j.xcrm.2020.100007

The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas

C. Ng, S. Piscuoglio, F. Geyer, et al.. (2017). Clinical Cancer Research. Cited 135 times. https://doi.org/10.1158/1078-0432.CCR-16-2857

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.

A. Mukhopadhyay, E. Plummer, A. Elattar, et al.. (2012). Cancer research. Cited 131 times. https://doi.org/10.1158/0008-5472.CAN-12-0324

APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis

J. Maciejowski, Aikaterini Chatzipli, Alexandra Dananberg, et al.. (2020). Nature genetics. Cited 127 times. https://doi.org/10.1038/s41588-020-0667-5

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.

Kosuke Tanaka, H. Yu, Shao-Hui Yang, et al.. (2021). Cancer cell. Cited 122 times. https://doi.org/10.1016/j.ccell.2021.07.006

APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.

R. Buisson, M. Lawrence, C. Benes, et al.. (2017). Cancer research. Cited 112 times. https://doi.org/10.1158/0008-5472.CAN-16-3389

The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.

B. Weigelt, R. Bi, Rahul Kumar, et al.. (2018). Journal of the National Cancer Institute. Cited 99 times. https://doi.org/10.1093/jnci/djy028

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

H. Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.. (2023). Nature. Cited 99 times. https://doi.org/10.1038/s41586-023-06303-1

APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors

N. Roper, Shaojian Gao, Tapan K Maity, et al.. (2019). Cell reports. Cited 97 times. https://doi.org/10.1016/j.celrep.2019.02.028

The mutational signatures of formalin fixation on the human genome

Qingli Guo, E. Lakatos, I. Bakir, et al.. (2021). Nature Communications. Cited 70 times. https://doi.org/10.1038/s41467-022-32041-5

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

D. Caswell, Philippe Gui, M. Mayekar, et al.. (2023). Nature Genetics. Cited 58 times. https://doi.org/10.1038/s41588-023-01592-8

Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.

Abby M. Green, K. Budagyan, Katharina E. Hayer, et al.. (2017). Cancer research. Cited 54 times. https://doi.org/10.1158/0008-5472.CAN-16-3394

Inhibiting APOBEC3 Activity with Single-Stranded DNA Containing 2′-Deoxyzebularine Analogues

M. Kvach, Fareeda M Barzak, S. Harjes, et al.. (2018). Biochemistry. Cited 38 times. https://doi.org/10.1021/acs.biochem.8b00858

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.

P. Selenica, A. Marra, N. J. Choudhury, et al.. (2022). Annals of oncology : official journal of the European Society for Medical Oncology. Cited 34 times. https://doi.org/10.1016/j.annonc.2022.09.151

Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.

D. Longo. (2019). The New England journal of medicine. Cited 28 times. https://doi.org/10.1056/NEJMe1914488

Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation

Tadahiko Matsumoto, Kotaro Shirakawa, M. Yokoyama, et al.. (2019). Scientific Reports. Cited 21 times. https://doi.org/10.1038/s41598-019-44407-9